AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02914665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously once daily for 7 consecutive days
Trial: NCT05316818
Drug: FOLFOXIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplet chemotherapy regimen consists from active three cytotoxic agents aiming to improve outcomes
Trial: NCT02451293
Drug: Melatonin (N-acetyl-5-methoxytryptamine)
RxNorm normalized name: N-Acetyl-5-methoxytryptamine
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02451293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03369951
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline is a semisynthetic derivative of tetracycline and is indicated for the treatment of infections due to susceptible isolates of designated microorganisms.
Trial: NCT01858740
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03371784
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: I.V. administration
Trial: NCT03371784
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. administration
Trial: NCT03971357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drops
Trial: NCT00117039
Drug: Aranesp®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03927144
Drug: AMG334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection
Trial: NCT00254475
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03747679
Drug: bosunitib sorbitol
RxNorm normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 Mg of bosutinib sorbitol solution
Trial: NCT04027751
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators administrated intravenously 0.9% saline solution as a placebo
Trial: NCT00836810
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.
Trial: NCT00271427
Drug: L-Selenomethionine
RxNorm normalized name: L-Selenomethionine Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03897335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group will not receive any aminophylline treatments for the first post-op five days
Trial: NCT00880217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule once daily for 42 days
Trial: NCT00880217
Drug: JNJ-31001074 3 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-mg capsule once daily for 42 days
Trial: NCT00880217
Drug: JNJ-31001074 1 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-mg capsule once daily for 42 days
Trial: NCT00880217
Drug: JNJ-31001074 10 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg capsule once daily for 42 days
Trial: NCT00234546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 injection at day 0. The study will last for 6 months in each patient.
Trial: NCT00003515
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT02463383
Drug: Placebo tab
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo tablet is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
Trial: NCT01620255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks
Trial: NCT01620255
Drug: PF-00547659 SC Injection
RxNorm normalized name: taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks
Trial: NCT01620255
Drug: PF-00547659 SC Injection
RxNorm normalized name: taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks
Trial: NCT01620255
Drug: PF-00547659 SC Injection
RxNorm normalized name: taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks
Trial: NCT01620255
Drug: PF-00547659 SC Injection
RxNorm normalized name: taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks
Trial: NCT03808922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nebulized qd x 7 OR 10 days
Trial: NCT03808922
Drug: DAS181 COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAS181 4.5mg nebulized q12h/day x 7 OR 10 days
Trial: NCT04207060
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One capsule of 50 mg of indomethacin will be taken orally twice a day for a total of 28 days.
Trial: NCT04207060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule of lactose not containing active study drug will be taken orally twice a day for a total of 28 days.
Trial: NCT01452919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04085757
Drug: long interval dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A small envelope including two labeled plastic bags (A \& B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
Trial: NCT04085757
Drug: short interval dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A small envelope including two labeled plastic bags (A\& B) (each bag containing either 1 dinoprostone tablet(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
Trial: NCT03082092
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% intravenous saline (2.1ml) intravenously on induction of total knee replacement
Trial: NCT03269058
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of Dapagliflozin per day per os
Trial: NCT03100058
Drug: LIK066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIK066 will be supplied in different doses as tablets to be taken orally.
Trial: NCT03100058
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00516958
Drug: Topical Dermacyn
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Dermacyn once a day for 10 Days
Trial: NCT01875172
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00849719
Drug: PCA MO only
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When visual analog scale \[VAS\] exeeds 5/10, and after the PACU drug-blinded attending physician had established that the patient is coherent and cooperative, a PCA system will be connected to the patient's IV line. The physician will start device, and deliver the first bolus. The subsequent drug boluses will be self-administered by the patient. Group 2 will be administered with only boluses of 1.5 mg/bolus of MO, by request. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
Trial: NCT00439725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to placebo will receive a matching placebo tablet once daily.
Trial: NCT04181957
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants take one dose of placebo (lactose) tablet.
Trial: NCT03616509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 months on placebo, sodium chloride 0,9% injections
Trial: NCT05267977
Drug: Cephalosporin 1St Generation
RxNorm normalized name: CEPHALOSPORIN 1ST GENERATION
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05267977
Drug: Aminoglycosides
RxNorm normalized name: AMINOGLYCOSIDES
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02467582
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02867839
Drug: S-1 only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 cycles of adjuvant chemotherapy with S-1 only
Trial: NCT00905138
Drug: GLPG0259
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single ascending doses, oral solution
Trial: NCT00905138
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, oral solution
Trial: NCT00905138
Drug: GLPG0259
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, oral solution, 5 days
Trial: NCT00905138
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution, 5 days
Trial: NCT01400555
Drug: Cohort 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
Trial: NCT01400555
Drug: Cohort 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
Trial: NCT01400555
Drug: Cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
Trial: NCT01400555
Drug: Cohort 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
Trial: NCT01432457
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg and 100 mg placebo matching tablets taken orally once daily for 8 weeks; 1 week of placebo taper
Trial: NCT03869034
Drug: HAIC
RxNorm normalized name: Hepatic Arterial Infusion Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX-HAIC: oxaliplatin, 130 mg/m2 and leucovorin, 200 mg/m2, and fluorouracil, 400 mg/m2, bolus and 2400 mg/m2 over 46 hours Q3W D2 D3, for maximally 8 cycles, and the safety parameters are reviewed before the start of each course of HAIC treatment. Patients who achieve partial response (PR) or minor response (MR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and are assessed as eligible for R0 resection go on to undergo surgical resection. No other anti-tumor therapies are allowed before PD or postoperative relapse is confirmed.
Trial: NCT04465890
Drug: ASC22
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg/1ml/1bottle
Trial: NCT01645410
Drug: Atorvastatin Calcium Tablets, 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
Trial: NCT03278106
Drug: Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03746275
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 - 100 mg once daily according to local label
Trial: NCT03422354
Drug: General Aneasthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General Aneasthesia
Trial: NCT00935194
Drug: chinese medicinal herbs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200ml,p.o,qid,for 5 days
Trial: NCT00121277
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01843634
Drug: ODSH
RxNorm normalized name: Octasulfated Disaccharide Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03510910
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetaminophen 600 mg to be taken every 8 hours (TID)
Trial: NCT04295538
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion; Intravenous (IV)
Trial: NCT00982254
Drug: regular human insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection of 15 U regular human insulin; single dose administration on one separate dosing visit.
Trial: NCT03936062
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2nd generation sulfonylurea dispensing claim is used as the reference
Trial: NCT00069862
Drug: desferoxamine (DFO)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01679353
Drug: normal saline 0.5ml
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04147650
Drug: 0.10% VOS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
Trial: NCT04147650
Drug: 0.20% VOS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
Trial: NCT03263572
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intrathecally via spinal tap
Trial: NCT02019589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02376075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intake of Placebo, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
Trial: NCT05058118
Drug: FL058
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg、250mg、500mg、1000mg、1500mg、2000mg
Trial: NCT05058118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: empty bottle
Trial: NCT03097211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules. Orally, with 240 mL of potable water.
Trial: NCT03097211
Drug: BIA 6-512
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.
Trial: NCT03097211
Drug: Madopar® 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.
Trial: NCT02728245
Drug: Placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 table po qd
Trial: NCT00510744
Drug: pancreatic enzyme supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 caps with meals, 2 with snacks
Trial: NCT02153788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03575962
Drug: GSK3640254 bis-hydrochloride salt capsule
RxNorm normalized name: bile salts Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally (as single dose) on morning of Day 1, as 2 capsules of 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
Trial: NCT00878384
Drug: Medication to control ventricular rate in AF
RxNorm normalized name: Canesten AF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacologic rate control. Current therapy will be adjusted to achieve rate-control targets of \<80bpm and \<110bpm on exercise (6 minute walk). Where necessary, additional medication will be given as per standard practice (digoxin or beta-blocker). Typical does: Digoxin 62.5-250mcg o.d. ; Bisoprolol 1.25-20mg o.d.; Carvedilol 3.125-50mg b.d. ; Nebivolol 1.25-10mg o.d.
Trial: NCT00269854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be adminstered at Week 0, 2 and 6.
Trial: NCT00049517
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01354808
Drug: Dual Anti-Platelet Therapy (DAPT)
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Loading: aspirin 300mg + clopidogrel 600mg~* Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month
Trial: NCT01354808
Drug: Triple Anti-Platelet Therapy (TAPT)
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Loading: cilostazol 200mg + aspirin 300mg + clopidogrel 600mg~* Maintenance: cilostazol 100mg bid+ aspirin 200mg/d+ clopidogrel 75mg/d for 1 month
Trial: NCT03678987
Drug: mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will ingest mycophenolic acid as prescribed by their physician under the surveillance of an investigator.
Trial: NCT01106287
Drug: MK-0941
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period
Trial: NCT01106287
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single oral placebo will be administered in the designated period (Periods 1-5)
Trial: NCT04487574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Placebo 2 times a day during 14 days
Trial: NCT00424866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle: 0 µg/kg
Trial: NCT03242551
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC followed by T Chemotherapy with or without trastuzumab, i.e. Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days.
Trial: NCT01776424
Drug: Aspirin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin matching placebo, once daily, oral
Trial: NCT04476043
Drug: INCB054707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral; Tablet
Trial: NCT04476043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral; Tablet
Trial: NCT00364091
Drug: R89674 0.025% ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03916081
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive vehicle cream matched to roflumilast cream for topical application.
Trial: NCT02452450
Drug: Ibuprofen Acid
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02452450
Drug: Ibuprofen Sodium
RxNorm normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00903045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo twice a day
Trial: NCT00950430
Drug: F-18 FDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
Trial: NCT02161510
Drug: MK-2248
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days
Trial: NCT01743729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Lifitegrast Ophthalmic Solution 5.0%
Trial: NCT00049114
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no